Aug. 18 at 1:48 PM
$DFTX BofA analyst Tazeen Ahmad initiated coverage of Definium Therapeutics with a Buy rating and
$75 price target. The company's lead asset, DT120 - LSD - is in pivotal studies for major depressive disorder - MDD - and generalized anxiety disorder - GAD - with recent best-in-class potential demonstrated in the phase 3 studies for both indications, the analyst tells investors in a research note. If replicated in ongoing pivotal studies, the firm believes that DT120 could be a go-to option for patients with severe MDD and GAD, representing multi-billion dollar commercial opportunities, BofA added.
